Clinical Trial Update: Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting on safety and ECG data collection for brolucizumab 6 mg intravitreal treatment in wet age-related macular degeneration, with comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Wet Macular Degeneration

Drugs mentioned

• brolucizumab 6 mg (brolucizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Age-Related Macular Degeneration, Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2020-08-13